life science investing

Resonance Contracted by Major Global Pharma Company for Clinical Drug Trial

Read more

Radiopharm Theranostics CEO Shares Company Milestones as NASDAQ Listing

Read more

Quarterly Report for the Period Ended 30 September 2024

Read more

Significant Progress with B7-H3 Targeting Radio-Antibody (BetaBart)

Read more

Completion of Divesture of Non-US Assets

Read more

WOA Relocates Headquarters & Enhances German Facility Utilisation

Read more

Radiopharm Theranostics Targets Nasdaq Listing by End of 2024

Read more